InMed Pharmaceuticals (INM) Income from Non-Controlling Interests (2024 - 2025)
InMed Pharmaceuticals (INM) posted quarterly Income from Non-Controlling Interests of $20000.0 for Q2 2025, down 94.31% quarter-over-quarter from $351549.0 in Q4 2024.
InMed Pharmaceuticals (INM) Income from Non-Controlling Interests (2024 - 2025) Analysis & Trends
InMed Pharmaceuticals' Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at $20000.0 for Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.03 Mn | 790,206.45 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 20,000.00 |
| Dec 31, 2024 | 351,549.00 |